Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pediatrix Medical (MD) EBITDA Margin (2016 - 2025)

Pediatrix Medical (MD) has disclosed EBITDA Margin for 17 consecutive years, with 6.85% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 96.0% to 6.85% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.73%, a 1359.0% increase, with the full-year FY2025 number at 8.73%, up 1359.0% from a year prior.
  • EBITDA Margin was 6.85% for Q4 2025 at Pediatrix Medical, down from 14.61% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 14.61% in Q3 2025 to a low of 30.3% in Q2 2024.
  • A 5-year average of 2.87% and a median of 5.71% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -3588bps in 2024, then soared 3877bps in 2025.
  • Pediatrix Medical's EBITDA Margin stood at 13.64% in 2021, then tumbled by -57bps to 5.84% in 2022, then crashed by -524bps to 24.77% in 2023, then surged by 124bps to 5.9% in 2024, then rose by 16bps to 6.85% in 2025.
  • Per Business Quant, the three most recent readings for MD's EBITDA Margin are 6.85% (Q4 2025), 14.61% (Q3 2025), and 8.47% (Q2 2025).